UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Methods for cost control focus on rigorous allocation and review cycles, enabling proactive adjustments to keep spending in check.
22,624 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A durable, AI-driven demand backdrop is lifting HPE, Jabil, and CrowdStrike, prompting new targets and optimistic ass...
A big move by an asset manager can ripple through a stock’s price and its story. This article explains what asset man...
A Wharton analysis finds Social Security dampens wealth inequality, but solvency risks and policy changes could erode...
A coalition of rap legends led by Travis Scott takes a bold legal stand at the Supreme Court. This isn’t just a court...
When a fintech stock investor trims a large stake in a rising Brazilian payments firm, traders and everyday investors...
The NYC Council greenlights a 72-story Brooklyn tower with 1,263 units, a quarter permanently affordable. Constructio...
The latest nationwide data reveal a 7.6% drop in new foreclosure filings, but a closer look shows pockets of rising d...
PayPal faces a tough stretch in the public eye, yet cash flow and a disciplined capital plan hint at upside. Here’s w...
Brady Corporation, Pitney Bowes, and CompoSecure report stronger cash flow, expanding margins, and strategic bets in ...
The SEC has approved a slate of spot XRP ETFs, opening direct XRP exposure for retail and institutional investors wit...
Palantir's journey has been a roller coaster—massive gains, sharp pulls, and ongoing questions. This guide distills w...